|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Virginia Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Jaime E. Poquet Jornet
Ramón Jódar Masanés
Lluís Campins Bernadas
Tomás Casasín Edo
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 21 - Issue 2, April-June 2019
IMPACT OF INFUSION TIME ON THE COST OF INTRAVENOUS IMMUNOGLOBULIN THERAPY AT A TERTIARY HOSPITAL OUTPATIENT CLINIC
SERRAMONTMANY MORANTE EUGENIA, ALONSO MARTINEZ CARLA, ROIG IZQUIERDO ANNA, LOZANO ORTIN EVA, GORGAS TORNER MARIA QUERALT, MONTORO RONSANO JOSE BRUNO
Objective: To determine the economic impact of intravenous immunoglobulin (IVIG) infusion time on resource utilization and costs at an outpatient clinic.
Method: We performed an opportunity-cost and cost-minimization analysis of IVIG products available in Spain according to infusion time for two populations: adults with primary immunodeficiency (PI') and adults with autoimmune disease. The products studied were Intratect® 100 g/L, Plangamma® 50 g/L, Flebogamma® 'IF 100 g/L Gammagard® 50 g/L .iovig® 100 g/L Octagamocta® 100 g/L Privigen® 100 g/L.
Results: Based on the consideration that four infusion chairs are available for 12 hours a day, 200 days a year at the outpatient clinic and that the hospital receives €205 from the state for each intravenous treatment administered, regardless of infusion time, the opportunity-cost analysis showed that the hospital could generate an additional income of €189,771.42 for patients with PI' or autoimmune disease by using the fastest rather than the slowest IVIG product. The cost-minimization analysis showed that a patient with PI' would spend 52.07 or 73.91 hours a year at the outpatient clinic depending on whether the fastest or slowest IVIG product was used. This difference of 21.84 hours was even greater for patients with autoimmune disease (57.8 hours). The corresponding difference in annual productivity loss per patient was estimated at €150.11 for PI' and €397.35 for autoimmune disease.
Conclusions: Infusion rates should be taken into account when selecting an IVIG product. Products with shorter infusion times have a favorable impact on hospital budgets and could also improve patient quality of life.
COST-MINIMIZATION – ECONOMIC IMPACT – INFUSION RATE – INTRAVENOUS IMMUNOGLOBULIN – OPPORTUNITY COST – OUTPATIENT CLINIC